Seattle biotech Bonum raises $93M Series A round

Seattle-based biotech Bonum Therapeutics recently announced a $93 million Series A funding round, with participation from Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3×5 Partners and Codon Capital. The new funding will aid the company in advancing its technology and finding collaborators.

Earlier this year, the pharma giant Roche acquired its parent company, Good Therapeutics, for $250 million with potential milestone payments. Through the acquisition, Good Therapeutics launched Bonum to apply the technology to other products.

“We have enormous confidence in the Bonum team’s ability to advance a broad portfolio of first-in-class therapeutics through the development process,” Samuel Bjork, partner at Digitalis Ventures, said in a release. “With support from this strong syndicate of new and existing investors, Bonum is well positioned to deliver on the potential of its validated platform.”

READ THE STORY at Puget Sound Business Journal»